Proficio Capital Partners LLC Buys Shares of 10,174 TG Therapeutics, Inc. (NASDAQ:TGTX)

Proficio Capital Partners LLC bought a new stake in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 10,174 shares of the biopharmaceutical company's stock, valued at approximately $306,000.

Several other large investors have also recently bought and sold shares of TGTX. Amalgamated Bank raised its position in TG Therapeutics by 712.0% in the third quarter. Amalgamated Bank now owns 39,528 shares of the biopharmaceutical company's stock valued at $925,000 after purchasing an additional 34,660 shares during the last quarter. Principal Financial Group Inc. raised its position in TG Therapeutics by 1,549.4% in the third quarter. Principal Financial Group Inc. now owns 772,188 shares of the biopharmaceutical company's stock valued at $18,061,000 after purchasing an additional 725,371 shares during the last quarter. Los Angeles Capital Management LLC raised its position in TG Therapeutics by 33.7% in the third quarter. Los Angeles Capital Management LLC now owns 123,401 shares of the biopharmaceutical company's stock valued at $2,886,000 after purchasing an additional 31,124 shares during the last quarter. Entropy Technologies LP bought a new position in TG Therapeutics in the third quarter valued at about $730,000. Finally, Victory Capital Management Inc. raised its position in TG Therapeutics by 24.7% in the third quarter. Victory Capital Management Inc. now owns 32,679 shares of the biopharmaceutical company's stock valued at $764,000 after purchasing an additional 6,467 shares during the last quarter. 58.58% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, CFO Sean A. Power sold 10,021 shares of TG Therapeutics stock in a transaction on Monday, January 6th. The stock was sold at an average price of $28.53, for a total value of $285,899.13. Following the completion of the transaction, the chief financial officer now directly owns 660,611 shares in the company, valued at approximately $18,847,231.83. The trade was a 1.49 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 10.50% of the stock is currently owned by corporate insiders.

TG Therapeutics Trading Down 4.3 %

NASDAQ TGTX opened at $37.55 on Wednesday. The business has a 50 day simple moving average of $31.38 and a 200 day simple moving average of $28.77. TG Therapeutics, Inc. has a one year low of $12.93 and a one year high of $40.31. The stock has a market capitalization of $5.90 billion, a P/E ratio of -375.46 and a beta of 2.30. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91.

Remove Ads

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last posted its earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share for the quarter, beating analysts' consensus estimates of $0.08 by $0.07. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The company had revenue of $108.19 million for the quarter, compared to analyst estimates of $100.67 million. Research analysts expect that TG Therapeutics, Inc. will post 0.08 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on TGTX shares. StockNews.com raised TG Therapeutics from a "sell" rating to a "hold" rating in a research note on Tuesday, March 4th. HC Wainwright reissued a "buy" rating and issued a $55.00 price target on shares of TG Therapeutics in a research note on Tuesday, March 4th. Finally, JPMorgan Chase & Co. increased their price target on TG Therapeutics from $30.00 to $43.00 and gave the company an "overweight" rating in a research note on Monday, November 25th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $40.67.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.